Baclofen Patent Expiration
Baclofen was first introduced by Novartis Pharmaceuticals Corp
Baclofen Patents
Given below is the list of patents protecting Baclofen, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Lyvispah | US11491125 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | Sep 29, 2041 | Strides Pharma Intl |
| Lyvispah | US11850225 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | Sep 29, 2041 | Strides Pharma Intl |
| Ozobax | US10610502 | Oral baclofen solutions | Aug 30, 2039 | Rosemount |
| Lyvispah | US10792262 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | Jul 29, 2039 | Strides Pharma Intl |
| Lyvispah | US11654124 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | Jul 29, 2039 | Strides Pharma Intl |
| Lyvispah | US11931328 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | Jul 29, 2039 | Strides Pharma Intl |
| Fleqsuvy | US11324696 | Suspensions and diluents for metronidazole and baclofen | Sep 29, 2037 | Azurity |
| Fleqsuvy | US11446246 | Suspensions and diluents for metronidazole and baclofen | Sep 08, 2037 | Azurity |
| Kemstro | US6024981 | Rapidly dissolving robust dosage form |
Apr 09, 2018
(Expired) | Ucb Inc |
| Kemstro | US6221392 | Rapidly dissolving robust dosage form |
Apr 09, 2018
(Expired) | Ucb Inc |
Baclofen's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Baclofen:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
